Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
Sobi is dedicated to developing and delivering innovative therapies to improve the lives of rare disease patients.
About us Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. We are dedicated to capturing the scientific opportunities of our time. With our early roots in Sweden, we started as pioneers in Haemophilia. Today we are an innovative leader within rare diseases with a global reach. We are bringing ...
At Sobi everything starts with people.Understanding unmet medical needs is at our core. Combining this understanding with the capabilities in clinical development is our key to success.We have accumulated a strong expertise in rapidly and efficiently reaching people living with rare diseases with breakthrough therapies. Sobi’s operational network and strong professional relationships with ...
Discover Sobi’s key medicines and partner products for rare diseases, including haemophilia, rare kidney conditions, and immunological disorders.
At a glance Bringing brilliant ideas to life Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi in short: Global footprint with own presence in around 30 countries, delivering medicines to patients in many more Approximately 1,900 employees across Europe, North America, the Middle East ...
Sobi est une société biopharmaceutique internationale qui révèle le potentiel des thérapies innovantes et transforme le quotidien des personnes vivant avec une maladie rare.
About Sobi We Care About Patients Living with Rare and Severe Diseases At Sobi North America, we are inspired by a single vision – to be recognized as a global leader in providing innovative medicines that transform the lives of people with rare and debilitating diseases. Patients affected by rare diseases often face bigger challenges.